0001567619-22-001225.txt : 20220114
0001567619-22-001225.hdr.sgml : 20220114
20220114204551
ACCESSION NUMBER: 0001567619-22-001225
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20211221
FILED AS OF DATE: 20220114
DATE AS OF CHANGE: 20220114
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: BIENAIME JEAN JACQUES
CENTRAL INDEX KEY: 0001221590
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-26727
FILM NUMBER: 22533319
MAIL ADDRESS:
STREET 1: 925 PAGE MILL ROAD
CITY: PALO ALTO
STATE: CA
ZIP: 94304
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BIOMARIN PHARMACEUTICAL INC
CENTRAL INDEX KEY: 0001048477
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 680397820
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 105 DIGITAL DRIVE
CITY: NOVATO
STATE: CA
ZIP: 94949
BUSINESS PHONE: 4155066700
MAIL ADDRESS:
STREET 1: 105 DIGITAL DRIVE
CITY: NOVATO
STATE: CA
ZIP: 94949
4
1
doc1.xml
FORM 4
X0306
4
2021-12-21
0
0001048477
BIOMARIN PHARMACEUTICAL INC
BMRN
0001221590
BIENAIME JEAN JACQUES
C/O BIOMARIN PHARMACEUTICAL INC.
770 LINDARO ST.
SAN RAFAEL
CA
94901
1
1
0
0
Chief Executive Officer
Common Stock
2021-12-21
4
L
0
100
89.2246
A
303789
D
Common Stock
2022-01-12
4
M
0
5000
37.46
A
308789
D
Common Stock
2022-01-12
4
S
0
5000
89.00
D
303789
D
Common Stock
2022-01-13
4
M
0
5000
37.46
A
308789
D
Common Stock
2022-01-13
4
S
0
5000
87.86
D
303789
D
Common Stock
247533
I
Shares held by Jean-Jacques Bienaime Family Trust
Stock Option (Right to buy Common Stock)
37.46
2022-01-12
4
M
0
5000
0
D
2012-11-08
2022-05-07
Common Stock
5000
120000
D
Stock Option (Right to buy Common Stock)
37.46
2022-01-13
4
M
0
5000
0
D
2012-11-08
2022-05-07
Common Stock
5000
115000
D
Trade made pursuant to a 10b5-1 plan executed on October 13, 2021.
The sale reported in this Form 4 was matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, to the extent of 50 shares, with the reporting person's purchase of shares at a price of $78.7700 on September 9, 2021. The reporting person has agreed to pay to the Issuer the full amount of the profit realized by the reporting person in connection with the short-swing transaction, less transaction costs.
Reflects the number of options outstanding after the transactions from this specific stock option grant.
/s/ Eric Fleekop, Attorney-in-Fact
2022-01-14